Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
Ovarian Cancer and Us
OVARIAN CANCER and US
Ovarian Cancer and Us
Furthermore, our findings provide evidence that proficiency in NER or
MMR may account for mechanisms of PARPi resistance, other than mutation
reversal or p-glycoprotein up-regulation [55], to explain why BRCA mutated EOC patients do not respond favorably to Olaparib.
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.